MXCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MaxCyte Inc (MXCT) is not a strong buy for a beginner investor with a long-term focus at this moment. While the stock trades at a significant discount to cash per share and has strong fundamentals, the recent financial performance shows declining revenue, net income, and EPS. Additionally, there are no significant positive trading signals or recent news catalysts to support an immediate buy decision. A hold strategy is recommended until clearer positive trends emerge.
The MACD is positive and expanding, indicating a bullish momentum, but the RSI is neutral at 61.138, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level of 0.753, with key support at 0.714. Overall, the technical indicators do not strongly support a buy at this time.
The stock is trading at a 50% discount to cash per share, and the company is making progress with late-stage programs and new product launches. Gross margin has improved YoY to 63.68%.
Revenue, net income, and EPS have all declined YoY in the latest quarter. No significant trading trends from hedge funds or insiders. No recent news or congress trading data available. The stock has a 70% chance of a slight decline (-0.43%) in the next day.
In Q4 2025, revenue dropped by -16.02% YoY to $7.3M, net income fell by -9.45% YoY to -$9.596M, and EPS declined by -10.00% YoY to -0.09. However, gross margin increased by 2.66% YoY to 63.68%.
Craig-Hallum lowered the price target from $7 to $5 but maintained a Buy rating, citing strong fundamentals and an attractive risk-to-reward profile despite a weak quarter.
